2022 World Conference on Lung Cancer (ePosters)-EP08.01-007. Real-World Outcomes of Patients with Advanced Lung Adenocarcinoma Treated with First-Line Chemo-Immunotherapy in Italy

EP08.01-007. Real-World Outcomes of Patients with Advanced Lung Adenocarcinoma Treated with First-Line Chemo-Immunotherapy in Italy

Back to course

Pdf Summary

A study was conducted in Italy to evaluate the real-world clinical outcomes of chemo-immunotherapy (CT-IT) as a first-line treatment for patients with advanced lung adenocarcinoma (LUAC). The study included 642 patients who were enrolled in 42 Italian centers. The combination of cis/carboplatin, pemetrexed, and pembrolizumab was found to be effective and safe, with an overall response rate (ORR) of 42.7%. The most frequent site of disease progression was the lung. The median progression-free survival (PFS) was 10.1 months and the median overall survival (OS) was 15.2 months. Adverse events (AE) of grade 3 or higher occurred in 13.2% of patients, with neutropenia being the most common AE. <br /><br />The study findings support the effectiveness and safety of this first-line treatment approach in advanced LUAC patients, and they are consistent with the results of the KEYNOTE-189 study, which supported the use of CT-IT in this patient population. <br /><br />The median treatment duration was 7.6 months, and most patients completed the induction phase with all three drugs. However, 38.3% of patients discontinued one or more drugs, with pemetrexed being the most frequently discontinued drug. The most common reason for pemetrexed discontinuation was toxicity. <br /><br />The study also provided information on the baseline characteristics of the patients, including their age, sex, smoking status, performance status, sites of distant metastasis, and molecular alterations. <br /><br />In summary, this real-world study demonstrated the efficacy and safety of first-line CT-IT in patients with advanced LUAC. The treatment showed promising outcomes in terms of response rate and survival, and the adverse events associated with the treatment were manageable. These findings provide important real-world evidence to support the use of this treatment approach in clinical practice.

Asset Subtitle

Alessandro Leonetti

Meta Tag

Speaker Alessandro Leonetti

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

Italy

chemo-immunotherapy

CT-IT

lung adenocarcinoma

clinical outcomes

cis/carboplatin

pemetrexed

pembrolizumab

overall response rate

progression-free survival